Check for updates
Pediatric Blood & Cancer
SOCIÉTÉ INTERNATIONALE D’ONCOLOGIE PÉDIATRIQUE
aspho The American Society of Pediatric Hematology/Oncology
WILEY
INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY
Feasibility of indocyanine green-guided localization of pulmonary nodules in children with solid tumors
Abdelhafeez H. Abdelhafeez Suraj Sarvode Mothi3 Luca Pio1 Motomi Mori3
Teresa C. Santiago İD M. Beth McCarville ID Sue C. Kaste5
Alberto S. Pappo İD
Lindsay J. Talbot1,2 Andrew J. Murphy1,2 İD Andrew M. Davidoff1,2
1 Department of Surgery, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
2 Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA
3Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
4 Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
5 Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
6 Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
Correspondence
H.A. Abdelhafeez, Department of Surgery, MS 133, St. Jude Children’s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA. Email: Hafeez.Abdelhafeez@stjude.org
Funding information
NIH NCI, Grant/Award Number: 5P30CA021765-42; American Lebanese Syrian Associated Charities (ALSAC)
Abstract
Background: Clearing all pulmonary metastases is essential for curing pediatric solid tumors. However, intraoperative localization of such pulmonary nodules can be chal- lenging. Therefore, an intraoperative tool that localizes pulmonary metastases is needed to improve diagnostic and therapeutic resections. Indocyanine green (ICG) real-time fluorescence imaging is used for this purpose in adult solid tumors, but its utility in pediatric solid tumors has not been determined.
Methods: A single-center, open-label, nonrandomized, prospective clinical trial (NCT04084067) was conducted to assess the ability of ICG to localize pulmonary metastases of pediatric solid tumors. Patients with pulmonary lesions who required resection, either for therapeutic or diagnostic intent, were included. Patients received a 15-minute intravenous infusion of ICG (1.5 mg/kg), and pulmonary metastasectomy was performed the following day. A near-infrared spectroscopy iridium system was optimized to detect ICG, and all procedures were photo-documented and recorded.
Results: ICG-guided pulmonary metastasectomies were performed in 12 patients (median age: 10.5 years). A total of 79 nodules were visualized, 13 of which were not detected by preoperative imaging. Histologic examination confirmed the fol- lowing histologies: hepatoblastoma (n = 3), osteosarcoma (n = 2), and one each of rhabdomyosarcoma, Ewing sarcoma, inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, and papillary thy- roid carcinoma. ICG guidance failed to localize pulmonary metastases in five (42%) patients who had inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, or papillary thyroid carcinoma.
Conclusions: ICG-guided identification of pulmonary nodules is not feasible for all pediatric solid tumors. However, it may localize most metastatic hepatic tumors and high-grade sarcomas in children.
KEYWORDS fluorescence-guided localization, indocyanine green, near-infrared imaging, pulmonary metas- tases
Abbreviations: CT, computed tomography; EPR, enhanced permeability and retention; ICG, indocyanine green; IR, interventional radiology; NIR, near-infrared.
1 INTRODUCTION
The lung is the most common site of metastases for pediatric solid tumors.1 Reliable localization of pulmonary nodules is crucial for accu- rate staging, diagnosis, relapse, and therapeutic intervention. Localiza- tion techniques for pulmonary nodules include computed tomography (CT)-guided placement of a localizer (e.g., a hook, wire, or coil). How- ever, these approaches require transferring anesthetized patients from the interventional radiology (IR) suite to the operating room.2 Moreover, IR localization is associated with the risks of positioning inaccuracy, migration of the localizer, pneumothorax, and pain.2-8
Indocyanine green (ICG) is a water-soluble tricarbocyanine fluo- rophore that has an excellent safety profile and is approved by the U.S. Food and Drug Administration.9 Near-infrared (NIR) visualization of ICG can be performed either immediately after injection to assess the perfusion of tissues or in a delayed manner to exploit the differential retention of the ICG-plasma protein complex between tumor and nor- mal tissue at 24 hours. Tumor retention of ICG at 24 hours is thought to be caused by the enhanced permeability and retention (EPR) prop- erties of newly developed tumor vasculature, which has wide fenestra- tions that hold the ICG-plasma protein complex in the tumor mass. 10,11
Preclinical trials and adult clinical trials have shown that second- window imaging improves the precision of ICG-guided localization of pulmonary nodules.12-21 More recently, pediatric studies have demon- strated promising sensitivity and specificity of this technique for localizing hepatoblastoma pulmonary metastases.2,22-29 However, lit- tle is known about the feasibility of ICG-guided localization of other metastatic solid tumors. Therefore, we conducted a nonrandomized pilot study of the feasibility of ICG-guided localization of pulmonary metastases in a pediatric oncology population.
2 MATERIALS AND METHODS
2.1 Study design and participants
The ICGLOW protocol was a prospective, nonrandomized, open-label, single-arm, single-center clinical trial (NCT04084067) that included subjects in eight histologic groups. The study was approved by the Institutional Review Board of St. Jude Children’s Research Hospital, and written informed consent was obtained from parent/legal guardian and/or patient, as appropriate.
Patients with pulmonary metastases who required resection for therapeutic or diagnostic purposes were included. Patients with non-oncology-related lung pathology (i.e., benign pathologies) were excluded. The clinical trial used the second-window approach. Specif- ically, patients received a 15-minute intravenous infusion of ICG (1.5 mg/kg), and thoracoscopic or open pulmonary metastasectomy was performed the following day. Patients with Wilms tumor metas- tases were excluded from the study because of the “inverse” fluo- rescence pattern observed in our previous study, in which there was a hypo-fluorescence of the primary tumor and high ICG avidity of surrounding healthy kidney tissue.30
After the surgeon identified the pulmonary nodules by visual and/or tactile methods, the infrared camera and excitation probe with NIR wavelength were used. ICG was visualized using an iridium system (Visionsense Corp, Philadelphia, PA, USA) optimized for detecting the fluorophore. Images of the tumor field were displayed on a video screen, and the iridium system software measured the spectral reading from the nodule by capturing the NIR signal it emitted.
The entire resection procedure was photo-documented and recorded. ICG NIR fluorescence was evaluated and validated by two surgeons. All intraoperative and postoperative monitoring of patients was prospectively recorded to analyze any ICG-related adverse events.
2.2 Statistics
The primary endpoint of the trial was the ability of ICG NIR imaging to detect the presence of metastatic nodules in the lungs. A detection rate of 75% was considered standard (null), and 90% was desirable. Simon’s two-stage minimax design was adopted with 80% power and a 5% significance level. In the first stage, the accrual of 22 patients was planned. If true-positive nodules were detected (i.e., by ICG avidity and histology confirmation) in 17 or more cases, then the trial would progress to the second stage. However, if fewer than 17 cases had true-positive nodules, then the study would be stopped for futility.
3 RESULTS
Twelve patients (seven female and five male, median age 10.5 years [range: < 1 to 23 years]) underwent ICG-guided localization of pulmonary metastases. We detected 79 nodules intraoperatively. Histologic examination confirmed the following diagnoses: hep- atoblastomas (n = 3), osteosarcomas (n = 2), and one each of rhabdomyosarcoma, Ewing sarcoma, inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, and papillary thyroid carcinoma.
ICG guidance failed to localize pulmonary metastases in five (42%) patients, triggering a futility-stopping rule and indicating that the method is unlikely to achieve the desired detection rate of 90%. ICG guidance successfully localized all cases of metastatic hepatoblastoma (three patients) and high-grade sarcomas (four patients), including osteosarcoma, Ewing sarcoma, and rhabdomyosar- coma (Figure 1). However, the following tumors were not ICG avid: inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, and papillary thyroid carcinoma (Table 1). ICG failed to detect 21 nodules, which were detected intraoperatively via direct visualization and/or palpation, without any fluorescent signal. The lesions were removed and then analyzed by a pathologist, who confirmed them as true-positive nodules.
During the first stage, we observed a high false-negative rate, and it was not possible to achieve 17 or more true positives to reach
(A)
(B)
VisionSENSE
VisionSENSE
| Histology of pulmonary metastases | No. of patients | No. of nodules | Purpose of procedure | No. of true-positive nodulesª (No. of patients) | No. of nodules not detected by preoperative CT scans but detected by ICG NIR imaging (No. of patients) | Mean nodule size in cm (range) | Tumor necrosis (%) |
|---|---|---|---|---|---|---|---|
| Hepatoblastoma | 3 | 50 | Tx | 48 (3) | 13 (1) | 0.5 (0.1-1.8) | 0-90 |
| Osteosarcoma | 2 | 4 | Tx | 4 (2) | 0 | 2 (0.2-4) | 10-30 |
| Ewing sarcoma | 1 | 1 | Dx | 1 (1) | 0 | 1.4 | 0 |
| Rhabdomyosarcoma | 1 | 3 | Dx | 2 (1) | 0 | 0.3b | 0 |
| Atypical cartilaginous tumor | 1 | 1 | Tx | 0 | 0 | 0.9 | 0 |
| Inflammatory myofibroblastic tumor | 1 | 1 | Dx | 0 | 0 | 1.4 | 0 |
| Neuroblastoma | 1 | 17 | Tx | 0 | 0 | 0.5 (0.4-1.1) | 0-5 |
| Adrenocortical carcinoma | 1 | 1 | Tx | 0 | 0 | 1.2 | 0 |
| Papillary thyroid carcinoma | 1 | 1 | Dx | 0 | 0 | 0.4 | 0 |
Abbreviations: CI, confidence interval; cm, centimeters; CT, computed tomography; Dx, diagnosis; ICG, indocyanine green; NIR, near-infrared imaging; No., number; Tx, treatment.
ªDetection rate at the patient level = 53.84% (95% CI: 25.63%-82.04%); at the nodule level = 69.62% (95% CI: 59.84%-79.76%). bBoth true-positive rhabdomyosarcoma nodules were 0.3 cm.
statistical power. Therefore, after five false-negative results among the first 12 patients, we closed the metastatic pulmonary deposit histology group. For this current investigation, the accuracy of ICG positivity to locate an extrapulmonary metastatic deposit was determined by detection rates with 95% confidence intervals calculated at the metastatic nodule level and at the overall patient level.
We found no significant difference between the size of ICG-avid nodules (i.e., hepatoblastoma and sarcoma) and that of the other nod- ules that were not ICG avid. Preoperative CT imaging did not detect 13 of the 50 (26%) nodules related to primary liver tumors; however, those nodules were ICG avid, resulting in true-positive nodules at histologic analysis. No adverse events related to the use of ICG occurred in any of the patients.
4 DISCUSSION
This prospective clinical trial evaluated whether ICG NIR imaging con- sistently localizes metastatic pulmonary disease in pediatric patients with solid tumors. Accrual was stopped early, because our interim data analysis revealed that ICG accurately detected 75% of positive nodules; our target accuracy was 90%.
Patients enrolled in this trial could have any pediatric solid tumor histology, and the study failed to meet the threshold for detection in a small cohort with different histologies due to the absence of ICG avidity in several nodules with different pathologies. Therefore, ICG administered at a dose of 1.5 mg/kg and in a second-window strategy appeared to be unreliable for localizing metastatic pulmonary nodules
in this relatively small cohort with various pediatric solid tumors. To localize pulmonary deposits that are challenging because of their small nodule size or depth, an alternative approach (e.g., IR-guided localization) may be required. However, some solid tumors, includ- ing hepatoblastoma and high-grade sarcomas, may be amenable to ICG-guided localization, regardless of their size or depth.
Detailed analysis of the study data showed that all enrolled patients with metastatic hepatoblastoma demonstrated ICG-avid pulmonary nodules, and many nodules that were detected by ICG were not detected by preoperative CT scans. Furthermore, all four patients with high-grade sarcomas had ICG-avid metastatic pulmonary nodules. Therefore, we suggest wisely applying ICG NIR visualization during resections of pulmonary metastatic disease in pediatric patients with solid tumors, because of the potential avidity discrepancy across histologies. However, we recommend that this modality be considered in patients with hepatoblastoma or high-grade sarcoma. Future studies evaluating the utility of ICG-guided pulmonary nodule localization should focus on hepatoblastoma and high-grade sarcoma histologies.
The ICG-plasma protein complex is retained in the tumor microen- vironment due to its size and in the context of leaky tumor vasculature and defective tumor lymphatic clearance (i.e., the EPR effect). Different tumor histologies may have variable vascular permeability and intersti- tial fluid pressure, which in turn would result in variable EPRs.31,32 In addition, the variable rate of tumor neoangiogenesis after chemother- apy of different nonhepatic tumor-related metastases suggests the failure of ICG guidance is a histology-related event in our study or the effectiveness for some nonhepatic tumor metastases, including high-grade sarcomas.33,34
Multiple retrospective studies have shown a high success rate of localizing pulmonary metastases of hepatic primary tumors in pediatric populations. Those studies reported increased ICG uptake and impaired excretion of the fluorophore due to the tumor’s bil- iary characteristics.2,22-29 However, the literature lacks information about nonhepatic tumor-related metastases and the feasibility and effectiveness of ICG application in those cases.
Adult studies have shown the feasibility of ICG-guided localization of high-grade sarcomas.17,34-38 Similarly, our trial suggests that IGC- guided localization of pediatric high-grade sarcomas should be further investigated.
Earlier pediatric studies included variable doses and timing of ICG administration, with 0.2-0.75 mg/kg ICG intravenously infused 24-96 hours prior to surgery.28,35 This lack of standardization could jeopardize the use of ICG NIR imaging in children; thus, the aim of this study was to investigate the feasibility of ICG NIR imaging with a standardized approach for pediatric pulmonary metastasectomy. This study confirmed the safety of ICG in a pediatric oncology population. Although ICG side effects, including hypersensitivity and toxic reac- tions, have been reported in a few cases,39 no adverse events have been reported, even with a higher dose than that used in the available data on lung metastasectomy in children.35
The results of this trial merit further studies of ICG NIR imag- ing in pediatric oncology patients to improve our understanding of
the impact of tumor histology, prior treatment, tumor microenviron- ment, and tumor necrosis on the EPR phenomena and thereby ICG fluorescence. Targeting pulmonary cancer by utilizing tumor-specific receptors conjugated to a fluorophore has shown promising results in adult oncology studies,40,41 but the utility of this technique in the pediatric population is yet to be examined. Our study was designed to determine the feasibility of using ICG NIR imaging to detect pulmonary nodules of various histology groups.
This study has some limitations. The variability in the histologies of nonhepatic tumor metastases was the main limitation. Our results sug- gested the cautious application of ICG NIR imaging in these patients, depending on the histology of their tumor. Therefore, our conclusions are limited to histology-specific feasibility due to the study design and the relatively small number, overall, of enrolled patients. The inclusion of all pediatric solid tumors was another limitation of the study, with a subsequent limitation associated with the high false-negative rate. In addition, the study design proved that standardization of an ICG proto- col is feasible and effective in a limited category of tumors and should be adapted and modified for different tumors, according to their poten- tial EPR and histology modifications caused by chemotherapy. The utility of ICG-guided, histology-specific pulmonary nodule localization during metastectomy should be tested in prospective trials adopting universally applied gold standards.24
5 CONCLUSION
When a technical advancement in pediatric surgical oncology is intro- duced, a prospective protocol should be conducted to determine the method’s feasibility, safety, and effectiveness and to highlight potential limitations. In this pilot trial, we found that ICG-guided localization of metastatic pulmonary nodules was not successful for all pediatric solid tumors; however, this approach may be useful for metastatic hepatic tumors and high-grade sarcomas. Therefore, intraoperative ICG NIR imaging to detect pulmonary nodules warrants further investigation in prospective trials of larger cohorts with specific solid tumors.
ACKNOWLEDGMENTS
This work was supported by the NIH NCI 5P30CA021765-42 grant and the American Lebanese Syrian Associated Charities (ALSAC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
CONFLICT OF INTEREST STATEMENT
The authors declare they have no conflicts of interest.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
ORCID
Abdelhafeez H. Abdelhafeez ID https://orcid.org/0000-0002-7671- 3037
Teresa C. Santiago ID https://orcid.org/0000-0002-2838-3619 M. Beth McCarville [ https://orcid.org/0000-0002-2888-443X Alberto S. Pappo D https://orcid.org/0000-0002-5338-3979 Andrew J. Murphy D https://orcid.org/0000-0001-6747-0355
REFERENCES
1. Fuchs J, Seitz G, Handgretinger R, Schafer J, Warmann SW. Surgical treatment of lung metastases in patients with embryonal pediatric solid tumors: an update. Semin Pediatr Surg. 2012;21(1):79-87.
2. Morgan KM, Anderson KT, Johnston ME, et al. Interhospital variability in localization techniques for small pulmonary nodules in children: a pediatric surgical oncology research collaborative study. J Pediatr Surg. 2022;57(6):1013-1017.
3. Hwang S, Kim TG, Song YG. Comparison of hook wire versus coil localization for video-assisted thoracoscopic surgery. Thorac Cancer. 2018;9(3):384-389.
4. Mayo JR, Clifton JC, Powell TI, et al. Lung nodules: CT-guided place- ment of microcoils to direct video-assisted thoracoscopic surgical resection. Radiology. 2009;250(2):576-585.
5. McDaniel JD, Racadio JM, Patel MN, Johnson ND, Kukreja K. CT- guided localization of pulmonary nodules in children prior to video- assisted thoracoscopic surgical resection utilizing a combination of two previously described techniques. Pediatr Radiol. 2018;48(5):626- 631.
6. Morgan KM, Crowley JJ, BT Many, Lautz TB, Malek MM. Micro- coil localization as an effective adjunct to thoracoscopic resection of pulmonary nodules in children. J Pediatr Surg. 2021;56(1):142-145.
7. Parida L, Fernandez-Pineda I, Uffman J, Davidoff AM, Gold R, Rao BN. Thoracoscopic resection of computed tomography-localized lung nodules in children. J Pediatr Surg. 2013;48(4):750-756.
8. Heran MK, Sangha BS, Mayo JR, Blair G, Skarsgard ED. Lung nodules in children: video-assisted thoracoscopic surgical resection after com- puted tomography-guided localization using a microcoil. J Pediatr Surg. 2011;46(6):1292-1297.
9. Fineman MS, Maguire JI, Fineman SW, Benson WE. Safety of indo- cyanine green angiography during pregnancy: a survey of the retina, macula, and vitreous societies. Arch Ophthalmol. 2001;119(3):353- 355.
10. Jiang JX, Keating JJ, Jesus EM, et al. Optimization of the enhanced permeability and retention effect for near-infrared imaging of solid tumors with indocyanine green. Am J Nucl Med Mol Imaging. 2015;5(4):390-400.
11. Zeh R, Sheikh S, Xia L, et al. The second window ICG technique demon- strates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma. PLoS One. 2017;12(7):e0182034.
12. Kennedy GT, Newton A, Predina J, Singhal S. Intraoperative near-infrared imaging of mesothelioma. Transl Lung Cancer Res. 2017;6(3):279-284.
13. Predina JD, Newton A, Kennedy G, Lee MK, Singhal S. Near- infrared intraoperative imaging can successfully identify malignant pleural mesothelioma after neoadjuvant chemotherapy. Mol Imaging. 2017;16:153601211772378.
14. Predina JD, Newton AD, Corbett C, et al. A clinical trial of TumorGlow to identify residua disease during pleurectomy and decortication. Ann Thorac Surg. 2018;107(1):224-232.
15. Holt D, Okusanya O, Judy R, et al. Intraoperative near-infrared imaging can distinguish cancer from normal tissue but not inflammation. PLoS One. 2014;9(7):e103342.
16. Holt D, Parthasarathy AB, Okusanya O, et al. Intraoperative near- infrared fluorescence imaging and spectroscopy identifies residual tumor cells in wounds. J Biomed Opt. 2015;20(7):076002.
17. Keating J, Newton A, Venegas O, et al. Near-infrared intraoperative molecular imaging can locate metastases to the lung. Ann Thorac Surg. 2017;103(2):390-398.
18. Keating J, Singhal S. Novel methods of intraoperative localization and margin assessment of pulmonary nodules. Semin Thorac Cardiovasc Surg. 2016;28(1):127-136.
19. Keating JJ, Kennedy GT, Singhal S. Identification of a subcentimeter pulmonary adenocarcinoma using intraoperative near-infrared imag- ing during video-assisted thoracoscopic surgery. J Thorac Cardiovasc Surg. 2015;149(3):e51-e53.
20. Keating JJ, Okusanya OT, De JesusE, et al. Intraoperative molecular imaging of lung adenocarcinoma can identify residual tumor cells at the surgical margins. Mol Imaging Biol. 2016;18(2):209-218.
21. Newton AD, Predina JD, Frenzel-Sulyok LG, Shin MH, Wang Y, Singhal S. Intraoperative near-infrared imaging can identify sub-centimeter colorectal cancer lung metastases during pulmonary metastasectomy. J Thorac Dis. 2018;10(7):E544-E548.
22. Kitagawa N, Shinkai M, Mochizuki K, et al. Navigation using indo- cyanine green fluorescence imaging for hepatoblastoma pulmonary metastases surgery. Pediatr Surg Int. 2015;31(4):407-411.
23. Yamamichi T, Oue T, Yonekura T, et al. Clinical application of indocya- nine green (ICG) fluorescent imaging of hepatoblastoma. J Pediatr Surg. 2015;50(5):833-836.
24. Abdelhafeez A, Talbot L, Murphy AJ, Davidoff AM. Indocyanine green- guided pediatric tumor resection: approach, utility, and challenges. Front Pediatr. 2021;9:689612.
25. Cho YJ, Namgoong JM, Kwon HH, Kwon YJ, Kim DY, Kim SC. The advantages of indocyanine green fluorescence imaging in detecting and treating pediatric hepatoblastoma: a preliminary experience. Front Pediatr. 2021;9:635394.
26. Hiyama E. Fluorescence image-guided navigation surgery using indo- cyanine green for hepatoblastoma. Children (Basel). 2021;8(11):1015.
27. Lake CM, Bondoc AJ, Dasgupta R, et al. Indocyanine green is a sensi- tive adjunct in the identification and surgical management of local and metastatic hepatoblastoma. Cancer Med. 2021;10(13):4322-4343.
28. Whitlock RS, Patel KR, Yang T, Nguyen HN, Masand P, Vasudevan SA. Pathologic correlation with near infrared-indocyanine green guided surgery for pediatric liver cancer. J Pediatr Surg. 2022;57(4):700-710.
29. Yoshida M, Tanaka M, Kitagawa N, et al. Clinicopathological study of surgery for pulmonary metastases of hepatoblastoma with indocyanine green fluorescent imaging. Pediatr Blood Cancer. 2021;69(7):e29488.
30. Abdelhafeez AH, Murphy AJ, Brennan R, et al. Indocyanine green- guided nephron-sparing surgery for pediatric renal tumors. J Pediatr Surg. 2022;57(9):174-178.
31. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54(13):3352-3356.
32. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.
33. Taskinen S, Lohi J, Koskenvuo M, Taskinen M. Evaluation of effect of preoperative chemotherapy on Wilms’ tumor histopathology. J Pediatr Surg. 2018;53(8):1611-1614.
34. Oda Y, Tanaka K, Hirose T, Hasegawa T, et al. Standardization of evalu- ation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas. BMC Cancer. 2022;22(1):94.
35. Goldstein SD, Heaton TE, Bondoc A, et al. Evolving applications of flu- orescence guided surgery in pediatric surgical oncology: a practical guide for surgeons. J Pediatr Surg. 2021;56(2):215-223.
36. Predina JD, Newton AD, Corbett C, et al. Near-infrared intraoper- ative imaging for minimally invasive pulmonary metastasectomy for sarcomas. J Thorac Cardiovasc Surg. 2019;157(5):2061-2069.
37. Okusanya OT, Holt D, Heitjan D, et al. Intraoperative near- infrared imaging can identify pulmonary nodules. Ann Thorac Surg. 2014;98(4):1223-1230.
38. Shafy SZ, Hakim M, Lynch S, Chen L, Tobias JD. Fluorescence imag- ing using indocyanine green dye in the pediatric population. J Pediatr Pharmacol Ther. 2020;25(4):309-313.
39. Meira J, Marques ML, Falcão-Reis F, et al. Immediate reactions to fluorescein and indocyanine green in retinal angiography: review of literature and proposal for patient’s evaluation. Clin Ophthalmol. 2020;14:171-178.
40. Predina JD, Newton A, Deshpande C, Low P, Singhal S. Utilization of targeted near-infrared molecular imaging to improve pulmonary metastasectomy of osteosarcomas. J Biomed Opt. 2018;23(1):1-4. doi: 10.1117/1.jbo.23.1.016005
41. Azari F, Kennedy G, Bernstein E, et al. Evaluation of OTL38-generated tumor-to-background ratio in intraoperative molecular imaging- guided lung cancer resections. Mol Imaging Biol. 2021;25(1):85-96.
How to cite this article: Abdelhafeez AH, Mothi SS, Pio L, et al. Feasibility of indocyanine green-guided localization of pulmonary nodules in children with solid tumors. Pediatr Blood Cancer. 2023;70:e30437. https://doi.org/10.1002/pbc.30437